Human mutations in the transcription factor gene, SOX9, cause campomelic dy
splasia (CD), a severe dwarfism associated with brain abnormalities includi
ng dilation of lateral ventricles. hypoplasia of the corpus callosum and ce
rebellum defects. To improve our understanding of how SOX9 contributes to t
he molecular genetic pathway of brain development we sought to investigate
the distribution of SOX9 protein in rat and mouse brain. The regions of SOX
9 expression identified in this study correlated with the sites of reported
brain abnormalities in CD patients. SOX9 immunoreactivity was observed in
nuclei of scattered cells throughout the brain, in the ependymal layer and
cells of the choroid plexus. In the forebrain most SOX9-immunoreactive nucl
ei co-localised with the glial astrocyte marker S-100. In the cerebellum SO
X9 was observed mostly in cells surrounding Purkinje cells, which were iden
tified, by electron microscopy, as Golgi epithelial cells, also known as Be
rgmann glia. Using SOX9 antibody as a marker for the precursors of Bergmann
glia, we traced their origin during mouse development. At embryonic day (E
)14.5 and E16.5, SOX9 immunoreactivity was present mainly in the primordial
choroid plexus, and ventricular zone. By E18.5. SOX9 was observed in the g
ranular cell and Purkinje cell layers but no labelling was detectable in th
e external granular layer. These results suggest that SOX9 immunoreactivity
is a marker for Bergmann cells during development and favour the proposed
origin of the secondary glial scaffold arising from Bergmann cells derived
exclusively from the ventricular zone. (C) 2001 Elsevier Science B.V. All r
ights reserved.